A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 51
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : HAQ-DI
Long Form : HAQ Disability Index
No. Year Title Co-occurring Abbreviation
2022 Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. bDMARDs, CDAI
2022 Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study. EQ-5D, PGA-VAS, QoL, ROA, WPAI
2021 Assessment of disability in idiopathic inflammatory myopathy: a call for linearity. ALDS, CSMs, IIM, TIS
2021 Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study. bDMARDs, EORA, SAEs, SDAI
2021 Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors. DAPSA, DAS28-CRP, EULAR, IXE, MDA, PBO, TNFi
2021 Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. CSMs, IIMs, MMT, PAMs, Pt global
2021 Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort. UA
2021 Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. FACIT-F, LSM, MCIDs, PCS, PROs, PtGA, VAS
2020 A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. GPH, MDHAQ, PROMIS
10  2020 Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. CDAI
11  2020 Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. ACR20, Ref-RTX, SDZ-RTX
12  2020 Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. FACIT, HRQoL, LSM, PROs, PtGA, UPA, WPAI
13  2019 Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. DSS, mRSS, PCS
14  2019 Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. GI
15  2019 Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review. AHSCT, ASSIST, EQ-5D, HRQoL
16  2018 Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. AEs
17  2018 Rasch measurement in rheumatoid arthritis: deriving psychometrically optimal measures from the Rasch Everyday Activity Limitation item bank. CAT, REAL, REAL-6
18  2017 Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. CHFS, mRSS, SF36
19  2017 Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. PASS, TCZ
20  2017 Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. RCTs
21  2016 Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. GIS, PCS and MCS, SF
22  2016 Racial differences in health-related quality of life and functional ability in patients with gout. GIS, HRQoL, MCS, SF-36
23  2015 Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS() Physical Function. CER, HAQ, IRT, PF, PROMIS, SF-36 PF
24  2015 Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. ADA, SDAI
25  2015 Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. HRCT, ILD, SGRQ, VAS
26  2015 Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. LDA, mTSS
27  2015 Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. ICF, PROMIS
28  2014 Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. ---
29  2014 Measurement properties of the Health Assessment Questionnaire Disability Index for generalized osteoarthritis. GOA
30  2014 Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. ---
31  2014 Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). CRRP, EORA, LDA, nbDMARDs, TNFis
32  2013 Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. REACTION, TCZ, TNF-IR
33  2013 Psychometric properties of the Swedish version of the Scleroderma Health Assessment Questionnaire and the Cochin Hand Function Scale in patients with systemic sclerosis. CHFS, dcSSc, lcSSc, SSc HAQ, VAS
34  2013 The Gout Assessment Questionnaire 2.0: cross-cultural translation into Dutch, aspects of validity and linking to the International Classification of Functioning, Disability and Health. GAQ2.0, GI, ICC, ICF
35  2012 Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. CRP, IA, KJAI, MNC, MST, SF, SpA, ST, THOMP, US
36  2012 Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. CZP
37  2012 Rheumatoid arthritis and falls: the influence of disease activity. CRT, TIT, TUG
38  2011 Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. DAS-28, GCs
39  2011 MDHAQ/RAPID3 scores: quantitative patient history data in a standardized "scientific" format for optimal assessment of patient status and quality of care in rheumatic diseases. CQI, MDHAQ, RADAI, VAS
40  2011 Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study. CES-D, FACIT-Fatigue, MOS Sleep Scale, PRO, s.d
41  2010 Comparison of measures of functional disability in patients with gout. ---
42  2010 Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. CATPCA, EScSG, HAI, mRSS
43  2010 Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. mRSS, RCTs
44  2010 Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. CZP, FAS, MCIDs
45  2010 Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. mRSS, SJC, TFRs
46  2008 Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. QALY
47  2007 Results of the Health Assessment Questionnaire for Japanese patients with systemic sclerosis--measuring functional impairment in systemic sclerosis versus other connective tissue diseases. dSSc, HAQ, lSSc, SSc
48  2006 Validation and crosscultural adaptation of an argentine spanish version of the health assessment questionnaire disability index. HAQ, RA
49  2005 The Health Assessment Questionnaire (HAQ). HAQ, PROMIS, PROs, VAS
50  2003 Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. HAQ, MTX, RA
51  1993 How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). RA